[1]万光明,王明阳.重视视网膜下注射技术的临床应用[J].眼科新进展,2024,44(4):253-257.[doi:10.13389/j.cnki.rao.2024.0050]
　WAN Guangming,WANG Mingyang.Clinical application of subretinal injection[J].Recent Advances in Ophthalmology,2024,44(4):253-257.[doi:10.13389/j.cnki.rao.2024.0050]
点击复制

重视视网膜下注射技术的临床应用/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
44卷
期数:
2024年4期
页码:
253-257
栏目:
述评
出版日期:
2024-04-05

文章信息/Info

Title:
Clinical application of subretinal injection
作者:
万光明; 王明阳
450052　河南省郑州市，郑州大学第一附属医院眼科
Author(s):
WAN Guangming; WANG Mingyang
Department of Ophthalmology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan Province,China
关键词:
视网膜下注射; 基因治疗; 细胞治疗; 玻璃体视网膜手术
Keywords:
subretinal injection;  gene therapy;  cell therapy;  vitreoretinal surgery
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2024.0050
文献标志码:
A
摘要:
视网膜下腔是位于视网膜色素上皮层和感光细胞层之间的潜在腔隙。视网膜下注射是将治疗药物输送到视网膜下腔的一种给药方式。与玻璃体内注射相比，视网膜下注射药物对视网膜光感受器细胞和视网膜色素上皮细胞的作用更直接、更有效。近年来，随着医疗技术的进步和手术器械的更新与发展，视网膜下注射的临床应用范围逐渐拓宽，已成为多种眼底疾病基因治疗和细胞治疗的重要给药方式，在玻璃体视网膜手术中的作用也日益显著。本文将从视网膜下注射的适应证、方法与技巧以及潜在风险与并发症等方面进行探讨。
Abstract:
The subretinal space is a potential area between the retinal pigment epithelium layer and the photoreceptor layer. Subretinal injection is a way of drug administration to the subretinal space. Compared with intravitreal injection, subretinal injection allowed drugs to take more direct and effective action on retinal photoreceptor cells and retinal pigment epithelial cells. In recent years, thanks to advances in medical technology and surgical instrumentation subretinal injection realizes a gradually expanded clinical application, becoming an important drug delivery method for gene therapy and cell therapy of various fundus oculi diseases and playing an increasingly prominent role in vitreoretinal surgery. This article will explore the indications, techniques, potential risks, and complications of subretinal injection.

参考文献/References:

［1］　DEL AMO E M,RIMPELA A K,HEIKKINEN E,KARI O K,RAMSAY E,LAJUNEN T,et al.Pharmacokinetic aspects of retinal drug delivery［J］.Prog Retin Eye Res,2017,57,134-185.
［2］　LI T,ADAMIAN M,ROOF D J,BERSON E L,DRYJA T P,ROESSLER B J,et al.In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector［J］.Invest Ophthalmol Vis Sci,1994,35(5):2543-2549.
［3］　MEYER C H,SZURMAN P,HARITOGLOU C,MAIER M,WOLF A,LYTVYNCHUK L,et al.Application of subretinal fluid to close refractory full thickness macular holes:treatment strategies and primary outcome:APOSTEL study［J］.Graefes Arch Clin Exp Ophthalmol,2020,258(10):2151-2161.
［4］　SHULMAN M,SEPAH Y J,CHANG S,ABRAMS G W,DO D V,NGUYEN Q D.Management of retained subretinal perfluorocarbon liquid［J］.Ophthalmic Surg Lasers Imaging Retina,2013,44(6):577-583.
［5］　CHALAM K V,GASPARIAN S.Successful delivery of subretinal aflibercept (new surgical technique) for the treatment of submacular hemorrhage in idiopathic polypoidal choroidal vasculopathy［J］.J Surg Case Rep,2021,2021(8):rjab358.
［6］　SCHNEIDER N,SUNDARESAN Y,GOPALAKRISHNAN P,BERYOZKIN A,HANANY M,LEVANON E Y,et al.Inherited retinal diseases:linking genes,disease-causing variants,and relevant therapeutic modalities［J］.Prog Retin Eye Res,2022,89:101029.
［7］　GUPTA P R,HUCKFELDT R M.Gene therapy for inherited retinal degenerations:initial successes and future challenges［J］.J Neural Eng,2017,14(5):051002.
［8］　IRIGOYEN C,AMENABAR ALONSO A,SANCHEZ-MOLINA J,RODRGUEZ-HIDALGO M,LARA-LPEZ A,RUIZ-EDERRA J.Subretinal injection techniques for retinal disease:a review［J］.J Clin Med,2022,11(16):4717.
［9］　DOSMAR E,WALSH J,DOYEL M,BUSSETT K,OLADIPUPO A,AMER S,et al.Targeting ocular drug delivery:an examination of local anatomy and current approaches［J］.Bioengineering (Basel),2022,9(1):41.
［10］　RUSSELL S,BENNETT J,WELLMAN J A,CHUNG D C,YU Z F,TILLMAN A,et al.Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy:a randomised,controlled,open-label,phase 3 trial［J］.Lancet,2017,390(10097):849-860.
［11］　DRAG S,DOTIWALA F,UPADHYAY A K.Gene therapy for retinal degenerative diseases:progress,challenges,and future directions［J］.Invest Ophthalmol Vis Sci,2023,64(7):39.
［12］　VIGNAL-CLERMONT C,YU-WAI-MAN P,NEWMAN N J,CARELLI V,MOSTER M L,BIOUSSE V,et al.Safety of lenadogene nolparvovec gene therapy over 5 years in 189 patients with leber hereditary optic neuropathy［J］.Am J Ophthalmol,2023,249:108-125.
［13］　REICHEL F F,MICHALAKIS S,WILHELM B,ZOBOR D,MUEHLFRIEDEL R,KOHL S,et al.Three-year results of phase I retinal gene therapy trial for CNGA3-mutated Achromatopsia:results of a non randomised controlled trial［J］.Br J Ophthalmol,2022,106(11):1567-1572.
［14］　DING K,SHEN J,HAFIZ Z,HACKETT S F,SILVA R L E,KHAN M,et al.AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression［J］.J Clin Invest,2019,129(11):4901-4911.
［15］　KHANANI A M,BOYER D S,WYKOFF C C,REGILLO C D,BUSBEE B G,PIERAMICI D,et al.Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC):a prospective,two-year,multicentre phase 1 study［J］.EClinicalMedicine,2024,67:102394.
［16］　万光明,余川.重视不同来源移植细胞在视网膜退行性疾病中的替代治疗作用［J］.眼科新进展,2022,42(8):589-596.
WAN G M,YU C.Effect of the replacement therapy of transplanted cells from different sources in retinal degenerative diseases［J］.Rec Adv Ophthalmol,2022,42(8):589-596.
［17］　BEN M’BAREK K,MONVILLE C.Cell therapy for retinal dystrophies:from cell suspension formulation to complex retinal tissue bioengineering［J］.Stem Cells Int,2019,2019:4568979.
［18］　COCO-MARTIN R M,PASTOR-IDOATE S,PASTOR J C.Cell replacement therapy for retinal and optic nerve diseases:cell sources,clinical trials and challenges［J］.Pharmaceutics,2021,13(6):865.
［19］　SCHWARTZ S D,HUBSCHMAN J P,HEILWELL G,FRANCO-CARDENAS V,PAN C K,OSTRICK R M,et al.Embryonic stem cell trials for macular degeneration:a preliminary report［J］.Lancet,2012,379(9817):713-720.
［20］　周琪,祝贺,谭元卿,郝捷,王磊,王柳.一种用于视网膜色素上皮细胞的培养液及其制备方法和应用:CN105838676B［P］.2020-06-05.
ZHOU Q,ZHU H,TAN Y,HAO J,WANG L,WANG L.Culture solution for retinal pigment epitheliums and preparation method and application thereof:CN105838676B［P］.2020-06-05.
［21］　纳涛,王磊,郝捷,张可华,韩晓燕,周琪,等.人胚胎干细胞来源的视网膜色素上皮细胞质量控制研究［J］.生命科学,2018,30(3):248-260.
NA T,WANG L,HAO J,ZHANG K H,HAN X Y,ZHOU Q,et al.The quality control studies on human embryonic stem cells-derived retinal pigment epithelial cells［J］.Chin Bull Life Sci,2018,30(3):248-260.
［22］　YIU G,MAHMOUD T H.Subretinal hemorrhage［J］.Dev Ophthalmol,2014,54:213-222.
［23］　FLEISSIG E,BARAK A,GOLDSTEIN M,LOEWENSTEIN A,SCHWARTZ S.Massive subretinal and subretinal pigment epithelial hemorrhage displacement with perfluorocarbon liquid using a two-step vitrectomy technique［J］.Graefes Arch Clin Exp Ophthalmol,2017,255(7):1341-1347.
［24］　LIMON U,GEZGINASLAN T A,SAYGIN IO,BOZKURT E,KARDES E,AKCAY B I S.Efficacy of simultaneous application of subretinal tissue plasminogen activator and bevacizumab for submacular hemorrhages［J］.Beyoglu Eye J,2023,8(3):198-207.
［25］　TEWARI A,ELIOTT D,SINGH CN,GARCIA-VALENZUELA E,ITO Y,ABRAMS G W.Changes in retinal sensitivity from retained subretinal perfluorocarbon liquid［J］.Retina,2009,29(2):248-250.
［26］　GARCA-ARUM J,CASTILLO P,LPEZ M,BOIXADERA A,MARTNEZ-CASTILLO V,PIMENTEL L.Removal of retained subretinal perfluorocarbon liquid［J］.Br J Ophthalmol,2008,92(12):1693-1694.
［27］　万光明,刘舒静,梁申芝,钱诚,王炯,郑玉宝.38G针头抽吸视网膜下残留重水小滴三只眼［J］.中华眼底病杂志,2018,34(2):172-173.
WAN G M,LIU S J,LIANG S Z,QIAN C,WANG J,ZHENG Y B.38G needle aspirates residual heavy water droplets under retina in three eyes［J］.Chin J Ocul Fundus Dis,2018,34(2):172-173.
［28］　ROMANO M R,ROSSI T,BORGIA A,CATANIA F,SORRENTINO T,FERRARA M.Management of refractory and recurrent macular holes:a comprehensive review［J］.Surv Ophthalmol,2022,67(4):908-931.
［29］　MORIZANE Y,KIMURA S,HOSOKAWA M,SHIODE Y,HIRANO M,DOI S,et al.Planned foveal detachment technique for the resolution of diffuse diabetic macular edema［J］.Jpn J Ophthalmol,2015,59(5):279-287.
［30］　KADONOSONO K,YAMANE S,INOUE M,YAMAKAWA T,UCHIO E.Intra-retinal arterial cannulation using a microneedle for central retinal artery occlusion［J］.Sci Rep,2018,8(1):1360.
［31］　中华医学会眼科学分会眼底病学组,中国医师协会眼科医师分会眼底病专业委员会.中国视网膜下基因治疗药物注射术操作规范推荐专家共识(2022)［J］.中华实验眼科杂志,2022,40(10):887-893.
Fundus Disease Group in Ophthalmology Branch of Chinese Medical Association,Fundus disease Professional Committee of Ophthalmology Branch of Chinese Medical Doctor Association.Expert consensus on surgical technique for subretinal injection of gene therapy in China (2022)［J］.Chin J Exp Ophthalmol,2022,40(10):887-893.
［32］　OLUFSEN M E,SPINDLER L,SORENSEN N B,CHRISTIANSEN A T,ALBERTI M,HEEGAARD S,et al.Controlled subretinal injection pressure prevents damage in pigs［J］.Ophthalmologica,2022,245(3):285-294.
［33］　TAKAHASHI K,MORIZANE Y,HISATOMI T,TACHIBANA T,KIMURA S,HOSOKAWA M M,et al.The influence of subretinal injection pressure on the microstructure of the monkey retina［J］.PLoS One,2018,13(12):e0209996.
［34］　OKANOUCHI T,TOSHIMA S,KIMURA S,MORIZANE Y,SHIRAGA F.Novel technique for subretinal injection using local removal of the internal limiting membrane［J］.Retina,2016,36(5):1035-1038.
［35］　KWON H J,KWON O W,SONG W K.Semiautomated subretinal fluid injection method using viscous fluid injection mode［J］.Retina,2019,39(Suppl 1):S174-S176.
［36］　SHI T,XIE H,CHEN H.Modified Device for Subretinal Injection［J］.Retina,2022,42(1):224-226.
［37］　VASCONCELOS H M,LUJAN B J,PENNESI M E,YANG P,LAUER A K.Intraoperative optical coherence tomographic findings in patients undergoing subretinal gene therapy surgery［J］.Int J Retina Vitreous,2020,6(1):13.
［38］　STEEL D H,GERAGHTY B,KEARNS V,STANZEL B,WONG D.Subretinal injection under perfluorocarbon liquids to avoid foveal dehiscence［J］.Retina,2023,43(9):1612-1615.
［39］　TRIPEPI D,JALIL A,ALLY N,BUZZI M,MOUSSA G,ROTHSCHILD P R,et al.The role of subretinal injection in ophthalmic surgery:therapeutic agent delivery and other indications［J］.Int J Mol Sci,2023,24(13):10535.
［40］　PENG Y,TANG L,ZHOU Y.Subretinal injection:a review on the novel route of therapeutic delivery for vitreoretinal diseases［J］.Ophthalmic Res,2017,58(4):217-226.
［41］　SIMUNOVIC M P,SHAO E H,OSAADON P,SASONGKO M B,TOO L K.Two-step versus 1-step subretinal injection to compare subretinal drug delivery:a randomised study protocol［J］.BMJ Open,2021,11(12):e049976.
［42］　PENG J,LIANG T,CHEN C,ZHANG Q,XU Y,LIU J,et al.Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments［J］.Graefes Arch Clin Exp Ophthalmol,2020,258(5):1005-1012.

相似文献/References:

[1]陈娟 马晓晔.视网膜色素变性治疗最新进展[J].眼科新进展,2012,32(2):000.
[2]董敏 康刚劲.后发性白内障基因治疗的研究进展[J].眼科新进展,2013,33(10):000.
[3]吴国玖 查旭 张远平 曹霞 马林昆. 腺相关病毒载体用于外伤性视神经损伤基因治疗的研究进展[J].眼科新进展,2014,34(3):286.
[4]岳丽霞,徐积兄. 糖尿病视网膜病变基因治疗的研究进展[J].眼科新进展,2014,34(9):893.[doi:10.13389/j.cnki.rao.2014.0247]
[5]陈俊,杜毅,何剑峰.Leber遗传性视神经病变的治疗进展[J].眼科新进展,2017,37(7):684.[doi:10.13389/j.cnki.rao.2017.0174]
　CHEN Jun,DU Yi,HE Jian-Feng.Recent advances in treatment of Leber’s hereditary optic neuropathy[J].Recent Advances in Ophthalmology,2017,37(4):684.[doi:10.13389/j.cnki.rao.2017.0174]
[6]彭广华,王少军,杜璐.CRISPR/Cas9系统在视网膜发育与遗传性视网膜疾病研究中的应用[J].眼科新进展,2017,37(10):901.[doi:10.13389/j.cnki.rao.2017.0229]
　PENG Guang-Hua,WANG Shao-Jun,DU Lu.Application of CRISPR/Cas 9 system for the research of retinal development and inherited retinal diseases[J].Recent Advances in Ophthalmology,2017,37(4):901.[doi:10.13389/j.cnki.rao.2017.0229]
[7]管丽红,林俊堂.CRISPR-Cas9基因编辑技术在眼科疾病中的应用[J].眼科新进展,2018,38(9):801.[doi:10.13389/j.cnki.rao.2018.0190]
　GUAN Li-Hong,LIN Jun-Tang.Application of CRISPR-Cas9 technology in ophthalmological diseases[J].Recent Advances in Ophthalmology,2018,38(4):801.[doi:10.13389/j.cnki.rao.2018.0190]
[8]李润璞,金鑫.基因组编辑技术在遗传性视网膜营养不良基因治疗和细胞治疗中的应用[J].眼科新进展,2020,40(3):290.[doi:10.13389/j.cnki.rao.2020.0068]
　LI Runpu,JIN Xin.Application of genomic editing technology in gene therapy and cell therapy of inherited retinal dystrophies[J].Recent Advances in Ophthalmology,2020,40(4):290.[doi:10.13389/j.cnki.rao.2020.0068]
[9]李雨雨,李如意,李根林.视网膜色素变性行精准医疗的机制及方法进展[J].眼科新进展,2021,41(4):397.[doi:10.13389/j.cnki.rao.2021.0083]
　LI Yuyu,LI Ruyi,LI Genlin.The mechanism and methods of precision medicine for retinitis pigmentosa[J].Recent Advances in Ophthalmology,2021,41(4):397.[doi:10.13389/j.cnki.rao.2021.0083]
[10]张敬法,张宇萌,孙晓东.干性年龄相关性黄斑变性发病机制及治疗[J].眼科新进展,2022,42(3):169.[doi:10.13389/j.cnki.rao.2022.0035]
　ZHANG Jingfa,ZHANG Yumeng,SUN Xiaodong.Pathogenesis and treatment of dry age-related macular degeneration[J].Recent Advances in Ophthalmology,2022,42(4):169.[doi:10.13389/j.cnki.rao.2022.0035]

备注/Memo

备注/Memo:
国家重点研发计划项目（编号：2022YFC2404203）
更新日期/Last Update: 2024-04-05